This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tongers, J. Articles by Losordo, D. W. Search for Related Content PubMed PubMed Citation Articles by Tongers, J. Articles by Losordo, D. W. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Genes and Gene Therapy Leg Injuries and Disorders Related Collections Angiogenesis CV surgery: aortic and vascular disease Gene therapy

(Circulation. 2008;118:9-16.)
© 2008 American Heart Association, Inc.

Editorial

Therapeutic Angiogenesis for Critical Limb Ischemia

Microvascular Therapies Coming of Age

Jörn Tongers, MD; Jerome G. Roncalli, MD, PhD; Douglas W. Losordo, MD

From the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine, Northwestern University School of Medicine and Northwestern Memorial Hospital, Chicago, Ill.

Correspondence to Douglas W. Losordo, MD, Feinberg Cardiovascular Research Institute, Northwestern University, Tarry 12-703, 303 E Chicago Ave, Chicago, IL 60611. E-mail d-losordo@northwestern.edu

Key Words: Editorials • angiogenesis • gene therapy • peripheral vascular disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Despite progressive insights into the pathologies underlying coronary, cerebral, and peripheral artery atherosclerosis, these conditions continue to cause critical tissue ischemia and disability on an epidemic scale. For the past several decades, research and therapeutic development have focused on preventing or reversing occlusive disease in conduit vessels. The ultimate failure of macrovessel-targeted therapies is never more evident than in peripheral arterial disease, in which progressive disease leads to amputation at rates that have not changed significantly in 30 years. Despite modern therapy, up to 8 million Americans with peripheral arterial disease are devastated by immobility, intractable ischemia, ulceration, impaired wound healing, or amputation,¹ and the lack of additional treatment options leaves many patients with little hope for relief.

Article p 58

The concept of therapeutic angiogenesis evolved from pioneering work in the 1970s by Folkman,² who observed that the development and maintenance of an adequate microvascular supply is essential for the growth of neoplastic tissue. His hypothesis that the inhibition of "tumor angiogenic factors" would be effective against solid tumors was met with widespread skepticism, but 30 years of persistent research led to the development and approval of antiangiogenic treatments that now constitute a significant portion of the anticancer armamentarium. Soon after the identification of angiogenic growth factors, cardiovascular investigators began testing the hypothesis that stimulating angiogenesis could improve perfusion and function in ischemic tissues independent of macrovessel manipulation.³ Abundant preclinical data supported the safety and clinical potential of therapeutic angiogenesis that used growth factors or cellular-based strategies.^4,5 Accordingly, given . . . [Full Text of this Article]

This article has been cited by other articles:

				W. Schgoer, M. Theurl, J. Jeschke, A. G.E. Beer, K. Albrecht, R. Gander, S. Rong, D. Vasiljevic, M. Egger, A. M. Wolf, et al. Gene Therapy With the Angiogenic Cytokine Secretoneurin Induces Therapeutic Angiogenesis by a Nitric Oxide-Dependent Mechanism Circ. Res., November 6, 2009; 105(10): 994 - 1002. [Abstract] [Full Text] [PDF]

				A. Alfranca VEGF therapy: a timely retreat Cardiovasc Res, September 1, 2009; 83(4): 611 - 612. [Full Text] [PDF]